- Home
- IRIX vs BCTX Comparison
IRIX vs BCTX Comparison
Compare IRIX & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRIX
- BCTX
- Stock Information
- Founded
- IRIX 1989
- BCTX 2014
- Country
- IRIX United States
- BCTX Canada
- Employees
- IRIX N/A
- BCTX N/A
- Industry
- IRIX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- IRIX Health Care
- BCTX Health Care
- Exchange
- IRIX Nasdaq
- BCTX Nasdaq
- Market Cap
- IRIX 16.5M
- BCTX 13.7M
- IPO Year
- IRIX 1996
- BCTX N/A
- Fundamental
- Price
- IRIX $1.12
- BCTX $0.73
- Analyst Decision
- IRIX
- BCTX Strong Buy
- Analyst Count
- IRIX 0
- BCTX 1
- Target Price
- IRIX N/A
- BCTX $32.00
- AVG Volume (30 Days)
- IRIX 172.5K
- BCTX 834.1K
- Earning Date
- IRIX 08-12-2025
- BCTX 06-16-2025
- Dividend Yield
- IRIX N/A
- BCTX N/A
- EPS Growth
- IRIX N/A
- BCTX N/A
- EPS
- IRIX N/A
- BCTX N/A
- Revenue
- IRIX $49,744,000.00
- BCTX N/A
- Revenue This Year
- IRIX $9.61
- BCTX N/A
- Revenue Next Year
- IRIX N/A
- BCTX N/A
- P/E Ratio
- IRIX N/A
- BCTX N/A
- Revenue Growth
- IRIX 0.09
- BCTX N/A
- 52 Week Low
- IRIX $0.78
- BCTX $0.61
- 52 Week High
- IRIX $2.14
- BCTX $29.40
- Technical
- Relative Strength Index (RSI)
- IRIX 42.12
- BCTX 24.21
- Support Level
- IRIX $1.27
- BCTX $0.61
- Resistance Level
- IRIX $1.34
- BCTX $0.75
- Average True Range (ATR)
- IRIX 0.08
- BCTX 0.05
- MACD
- IRIX -0.03
- BCTX 0.08
- Stochastic Oscillator
- IRIX 10.85
- BCTX 54.76
About IRIX IRIDEX Corporation
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.